Company: Spark Therapeutics
Job title: Immunology Leader
Dr. Klaudia Kuranda is the Immunology Leader at Spark Therapeutics where she launched the Immunology Group and introduced multiple platforms to study the immunogenicity of gene therapy. She oversees execution/innovation of immunomonitoring in gene therapy trials and the design of pre-clinical studies of immune responses to therapeutic vectors. She began her scientific career at the French National Institute of Health and Medical Research (INSERM), studying various themes of human immunology. During last 5 years, she planned strategies for immunomonitoring in several gene therapy trials and her scientific work provided a comprehensive overview of distinct AAV immunity profiles in humans. She received her engineer’s degree in Biotechnology from the Warsaw University of Life Sciences (SGGW) in Poland and her Ph.D. in Microbiology from the National Institute of Applied Sciences (INSA) in France.
Live Q&A – Ask the speakers your questions 1:40 pm
day: Day Two
Considerations for Improved Measurement of the AAV-Specific Immune Responses 1:20 pm
• How to determine the AAV NAb titers in samples with matrix effect • Examine if its sufficient to only use IFNg ELISPOT to monitor T-cell activation in AAV-based gene therapy trials • Discuss whether animal models can predict immunogenicity of AAV in humansRead more
day: Day Two